Currently 169 patients have been enrolled in the EVADE study, of which 133 have been screen failed and 33 randomized and dosed.
The second half of December 2016 has been somewhat quieter due to end of the year celebrations. However, things picked up in January and February 2017 with very active screening activity (61 screenings in January and February). 49 sites have been activated in the following countries: Belgium, Croatia, Czech Republic, France, Greece, Hungary, Portugal and Spain.
Several sites have randomized their first patient over the last months. Congratulations go to Dr Ferhat Meziani’s site (Les Hôpitaux Universitaires de Strasbourg, France), which has successfully screened and randomized their first patient only a couple of days prior to Christmas! Further congratulations go to the Czech team, as both the site of Dr Hanauer (Nemocnice Decin, o.z.) and the site of Dr Novacek (Oblastni nemocnice Kolin) have randomized their first patient beginning of February 2017! The site of Dr Spapen (University Hospital Brussels, Belgium) and the site of Dr Nseir (University Hospital Lille, France) on the other hand have randomized their first patient in March 2017.
EVADE is a Phase II, randomized, controlled safety and efficacy trial of MEDI3902. It is a bispecific monoclonal antibody against two Pseudomonas aeruginosa proteins, for the prevention of ventilator-associated pneumonia in adult ICU-patients. In collaboration with MedImmune/AstraZeneca, up to 120 ICUs will participate in this study.